A nasal spray designed to boost the immune system against flu and colds has shown, in pre-clinical tests, that it can halt the viral reproduction of covid-19, the Australian biotechnology company responsible for the investigation said today.
The company Ena Respitarory, which develops the product INNA-051, indicated in a statement that the tests carried out with ferrets, coordinated by the deputy director of the Public Health agency in England, Miles Carroll, revealed 96% effectiveness.
The Australian company also indicated that the study, published today on the biomedical research portal bioRxiv, provided evidence that the synthetic molecule INNA-051 can be used as a method of preventive antiviral therapy and complement vaccination programs.
In addition to helping the most vulnerable people, the spray, which would be applied once or twice a week, also prevents infected people from spreading to others, said Christophe Demaison, director of Ena Respiratory.
The official also said that clinical trials of the substance will be carried out within the next four months.
The company has indicated that it has secured seven million euros from Australian investors to continue the investigation pending toxicity studies and the corresponding legal permits to be obtained.